Physician profile
Saima Chohan
NPI 1073675526
$21,985.12
in general payments reported to CMS, 2019-2025
58 companies · $2,515 in 2025
The $2,515 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,971 · 2020: $3,379 · 2021: $2,499 · 2022: $3,193 · 2023: $3,408 · 2024: $3,019 · 2025: $2,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,844 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,843.63 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,558.68 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $3,925.67 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $2,134.85 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,799.76 | 2019-2025 | |
| Horizon Therapeutics Plc | $1,599.74 | 2019-2023 | Krystexxa |
| Janssen Biotech, INC. | $1,245.51 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $882.57 | 2019-2024 | Taltz, Zepbound |
| Novartis Pharmaceuticals Corporation | $704.94 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $692.82 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $600.67 | 2019-2025 | Benlysta, Nucala |
| Genentech USA, INC. | $471.73 | 2019-2025 | Actemra, Rituxan |
| Fresenius Kabi USA, LLC | $388.71 | 2023-2025 | Idacio, Tyenne |
| Genzyme Corporation | $385.58 | 2019-2024 | |
| Radius Health, INC. | $366.77 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.18 | 2019-2025 | Cyltezo, Ofev |
Show all 43 companies
15 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saima Chohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.